Filtered By:
Specialty: Drugs & Pharmacology
Condition: Epilepsy

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 166 results found since Jan 2013.

Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights
Curr Neuropharmacol. 2021 Jun 8. doi: 10.2174/1570159X19666210608165509. Online ahead of print.ABSTRACTNeurological disorders like Alzheimer's disease (AD), Parkinson's disease (PD), stroke, amyotrophic lateral sclerosis, Huntington's disease (HD), epilepsy, traumatic brain injury (TBI), depression and anxiety are responsible for thousands of deaths worldwide every year. With the increase in life expectancy, there has been a rise in the prevalence of these disorders. Age is one of the major risk factors for these neurological disorders and with the aged population is set to rise to 1.25 billion by 2050. There is a growing ...
Source: Current Neuropharmacology - June 9, 2021 Category: Drugs & Pharmacology Authors: Namrata Pramod Kulkarni Bhupesh Vaidya Acharan Narula Shyam Sunder Sharma Source Type: research

Metabolic Aspects of Adenosine Functions in the Brain
Adenosine, acting both through G-protein coupled adenosine receptors and intracellularly, plays a complex role in multiple physiological and pathophysiological processes by modulating neuronal plasticity, astrocytic activity, learning and memory, motor function, feeding, control of sleep and aging. Adenosine is involved in stroke, epilepsy and neurodegenerative pathologies. Extracellular concentration of adenosine in the brain is tightly regulated. Adenosine may be generated intracellularly in the central nervous system from degradation of AMP or from the hydrolysis of S-adenosyl homocysteine, and then exit via bi-directio...
Source: Frontiers in Pharmacology - May 14, 2021 Category: Drugs & Pharmacology Source Type: research

Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases
Psychiatric disorders are frequently encountered in many neurological disorders, such as Alzheimer’s and Parkinson diseases along with epilepsy, migraine, essential tremors, and stroke. The most common comorbid diagnoses in neurological diseases are depression and anxiety disorders along with cognitive impairment. Whether the underlying reason is due to common neurochemical mechanisms or loss of previous functioning level, comorbidities are often overlooked. Various treatment options are available, such as pharmacological treatments, cognitive-behavioral therapy, somatic interventions, or electroconvulsive therapy. Howev...
Source: Frontiers in Pharmacology - May 13, 2021 Category: Drugs & Pharmacology Source Type: research

Caracole as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic
CONCLUSION: The data presented in this study support the beneficial impact of CAR on behavioural and neurochemical deficits. CAR benefits accrue because of its anti-apoptotic, antioxidant, and anti-inflammatory properties. Therefore, CAR has emerged as an alternative treatment for neurological disorders based on its properties.PMID:33970850 | DOI:10.2174/1871527320666210506185042
Source: CNS and Neurological Disorders Drug Targets - May 10, 2021 Category: Drugs & Pharmacology Authors: Mohammad Zamanian Ma łgorzata Kujawska Marjan Nikbakht Zadeh Amin Hassanshahi Soudeh Ramezanpour Zahra Kamiab Gholamreza Bazmandegan Source Type: research

The Role of ASIC1a in Epilepsy: A Potential Therapeutic Target
CONCLUSION: This review is intended to provide an overview of the structure, trafficking, and molecular mechanisms of ASIC1a in order to further elucidate the role of ASIC1a in epilepsy.PMID:33797385 | DOI:10.2174/1570159X19666210402102232
Source: Current Neuropharmacology - April 2, 2021 Category: Drugs & Pharmacology Authors: Yu Cheng Wuqiong Zhang Yue Li Ting Jiang Buhajar Mamat Yunhai Zhang Famin Wang Hongmei Meng Source Type: research

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
Study design and outcomes AbstractThe kynurenine pathway (KP) is the main path for tryptophan metabolism, and it represents a multitude of potential sites for drug discovery in neuroscience, including pain, stroke, and epilepsy. L ‐kynurenine (LKYN), the first active metabolite in the pathway, emerges to be a prodrug targeting glutamate receptors. The safety, tolerability, pharmacokinetics, and pharmacodynamics of LKYN in humans have not been previously investigated. In an open‐label, single ascending dose study, six part icipants received an intravenous infusion of 50, 100, and 150 µg/kg LKYN and new six participant...
Source: Pharmacology Research and Perspectives - March 9, 2021 Category: Drugs & Pharmacology Authors: Mohammad Al ‐Mahdi Al‐Karagholi, Jakob Møller Hansen, Dalia Abou‐Kassem, Anna Koldbro Hansted, Kumari Ubhayasekera, Jonas Bergquist, László Vécsei, Inger Jansen‐Olesen, Messoud Ashina Tags: ORIGINAL ARTICLE Source Type: research

The Pharmacological Action of Kaempferol in Central Nervous System Diseases: A Review
In conclusion, we suggest that KPF and some glycosylated derivatives (KPF-3-O-rhamnoside, KPF-3-O-glucoside, KPF-7-O-rutinoside, and KPF-4′-methyl ether) have a multipotential neuroprotective action in CNS diseases, and further studies may make the KPF effect mechanisms in those pathologies clearer. Future in vivo studies are needed to clarify the mechanism of KPF action in CNS diseases as well as the impact of glycosylation on KPF bioactivity.
Source: Frontiers in Pharmacology - January 13, 2021 Category: Drugs & Pharmacology Source Type: research

Allosteric modulation of the cannabinoid 2 receptor confers seizure resistance in mice.
Abstract Mounting evidence suggests that modulation of cannabinoid 2 receptors (CB2Rs) is therapeutic in mouse models of neurological disorders, including neuropathic pain, neurodegenerative disease, and stroke. We previously showed that reducing CB2R activity increases seizure susceptibility in mice. In the present study, we evaluated the therapeutic potential of the CB2R positive allosteric modulator, Ec21a, against induced seizures in mice. The pharmacokinetic profile of Ec21 demonstrated a similar distribution in brain and plasma, with detection up to 12 hours following injection. Ec21a increased resistance to...
Source: Neuropharmacology - January 12, 2021 Category: Drugs & Pharmacology Authors: Shapiro L, Gado F, Manera C, Escayg A Tags: Neuropharmacology Source Type: research

An Agathokakological tale of ∆9 -THC: Exploration of Possible Biological Targets.
Abstract ∆ 9 -Tetrahydrocannabinol (∆9 -THC), the active phytocannabinoid in cannabis, is virtually an adjunct to the endogenous endocannabinoid signaling system. By interacting with G-protein-coupled receptors CB1 and CB2, ∆9 -THC affects peripheral and central circulation by lowering sympathetic activity, altering gene expression, cell proliferation, and differentiation, decreasing leukocyte migration, modulating neurotransmitter release thereby modulating cardiovascular functioning, tumorigenesis, immune responses, behavioral and locomotory activities respectively. ∆ 9 -THC is effective in suppressing c...
Source: Current Drug Targets - September 30, 2020 Category: Drugs & Pharmacology Authors: Mathew B, Harilal S, Musa A, Kumar R, Parambi DGT, Jose J, Uddin MS, Shah MA, Behl T, Unnikrishnan MK Tags: Curr Drug Targets Source Type: research